Senseonics Bets Big on Direct Sales and Innovation Amid Strong Growth

GERMANTOWN, Md. – March 02, 2026 – Senseonics Holdings, Inc. (NASDAQ: SENS) is navigating a pivotal transformation, posting impressive revenue growth while undertaking an aggressive and costly strategic overhaul aimed at capturing a larger share of the competitive diabetes technology market. The company, known for its unique long-term implantable continuous glucose monitoring (CGM) system, reported a 72% year-over-year revenue surge in the fourth quarter of 2025, but the headline numbers are only part of a more complex story of investment, expansion, and calculated risk.

Alongside its strong financial performance, Senseonics announced a series of major operational milestones, including the critical CE Mark approval to launch its year-long Eversense 365 system in Europe and the U.S. rollout of its first integration with an automated insulin delivery (AID) system. These developments are coupled with a fundamental shift in its business model: taking full control of its commercial operations from partner Ascensia Diabetes Care, a move designed to accelerate growth but one that is already driving a sharp increase in spending.

A Strategic Overhaul for Market Share

The most significant change for Senseonics is its strategic pivot to a direct commercialization model, which took effect at the start of 2026. After years of relying on a partnership with Ascensia, Senseonics is now building its own sales and marketing infrastructure. The company is betting that direct control will allow for a more focused and aggressive push for its Eversense CGM, the only long-term implantable sensor on the market, which boasts a wear time of up to 365 days.

Early results from its increased investment in direct-to-consumer (DTC) marketing appear promising. The company reported a 103% growth in new U.S. patients in 2025 compared to the prior year, a surge it largely attributes to these campaigns. This strategy aims to build brand awareness and drive patient demand in a market dominated by giants like Dexcom and Abbott, whose products rely on shorter-term, externally worn sensors.

“In 2025, we took strategic actions to set the Company up for long term growth,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, in the company's announcement. “Successfully bringing commercial operations in-house and investing heavily in DTC marketing, we built the foundations necessary to achieve the full potential of the world’s first and only year-long CGM.”

The move is a bold gambit. By taking over its commercial fate, Senseonics gains the potential for higher revenue recognition and improved gross margins, which it projects will reach approximately 50% in 2026. However, it also assumes the substantial costs of a dedicated sales force, marketing campaigns, and distribution logistics, a reality reflected in its latest financial report.

Expanding Horizons: Europe and Next-Gen Tech

While restructuring its U.S. operations, Senseonics is also setting its sights on significant international expansion. The company recently secured CE Mark approval for the Eversense 365 system, clearing the path for its launch in the European Union. This opens up a massive new market, with initial rollouts planned for Germany, Italy, Spain, and Sweden in the coming months. While the opportunity is substantial, success in Europe will require navigating a complex web of country-specific reimbursement policies and building out a new commercial infrastructure, a process that will take time and resources.

Beyond market expansion, Senseonics is pushing forward with its innovation pipeline. The company has received Investigational Device Exemption (IDE) approval from the FDA to begin a pivotal trial for its next-generation Gemini sensor. This product represents a significant leap forward, designed as a self-powered, battery-enabled sensor that could potentially eliminate the need for the smart transmitter worn over the skin that current Eversense systems require. Successful development and approval of the Gemini could further differentiate Senseonics in the market, offering unparalleled convenience for users. The company expects to complete the pivotal trial in the second half of 2026, making it a key milestone for investors and patients to watch.

Further enhancing its current product's appeal, the company launched the integration of its Eversense 365 system with the twiist™ Automated Insulin Delivery (AID) System. This allows the long-term sensor to communicate directly with an insulin pump, creating a more comprehensive and automated diabetes management ecosystem, a feature that is becoming standard for top-tier CGM systems.

The High Cost of Growth

While Senseonics' strategic initiatives and revenue growth paint a picture of a company on the move, its financial statements reveal the high cost of this ambition. For the full year 2025, revenue grew an impressive 57% to $35.3 million. Gross profit saw a dramatic improvement, jumping to $15.8 million from just $0.5 million in 2024. However, the path to profitability remains distant.

The company’s selling, general, and administrative (SG&A) expenses more than doubled in the fourth quarter, rocketing to $19.8 million from $8.9 million in the same period of 2024. For the full year, these expenses increased by over $18 million. This surge is a direct result of the new strategy, reflecting increased spending on marketing personnel, promotional campaigns, and sales commissions as the company builds out its commercial team and invests in lead generation.

Consequently, the company reported a net loss of $20.8 million for the fourth quarter and $69.1 million for the full year. Although the annual loss narrowed slightly from 2024, the increased spending underscores the financial pressures of its strategic transition. Senseonics is essentially trading current profitability for future growth, a common strategy for emerging technology companies but one that carries inherent risk.

Looking ahead, Senseonics projects robust 2026 revenue of $58 million to $62 million, representing year-over-year growth between 65% and 76%. The company's ability to hit this target while managing its escalating operational costs will be the ultimate test of its new strategy. Investors will be watching closely to see if the significant upfront investments in direct sales and marketing can deliver the scale necessary to turn its innovative technology into a sustainably profitable business.